However, little is known about the effects of NF-κB inhibition in patients with metabolic disorders or any animal models of cardiac lipotoxicity and metabolic disorders including T2D, insulin resistance, and cardiac inflammation. This evidence concerns the gene NFKB1 and metabolic disease.